论文部分内容阅读
刘国恩教授为北京大学中国医药经济研究中心主任;博士生导师。曾在美国纽约市立大学研究院获得经济学博士(1991),师从卫生经济学家Michael Grossman教授;之后在哈佛大学William Hsiao教授指导下完成卫生经济学博士后(1994)。他曾执教美国南加利福尼亚大学(助理教授,1994-1999)、美国北卡大学(终身教授,2000-2006)。在国际学术活动方面,他担任“中国留美经济学会”(www．ChinaCES．org)2004-2005届主席、“国际医药经济及产出研究学会”(www．ISPOR．org)亚太联合会主席、以及该学会国际学术期刊《健康价值》Value in Health副主编、《国际应用经济学》杂志编委,以及世界银行健康、营养、及人口出版编委。在国内学术与政策咨询方面,他目前担任《中国药物经济学》总编、卫生部国家突发公共卫生事件专家委员会委员以及《中国卫生经济》杂志特邀编委等职。他的主要研究方向为健康与经济增长、医疗体制改革以及医药经济成本效益分析。他主持过多项有关中国医疗体制改革、卫生经济以及人口政策的科研项目,曾与卫生部合作,对中国医疗保险改革的“两江”试点进行过系统性评估。
Professor Liu Guoen is Peking University China Medical Economics Research Center Director; PhD supervisor. He received his Ph.D. in Economics from the City University of New York in the United States (1991), a professor of health economist Michael Grossman, and a postdoctoral fellow in Health Economics under the guidance of Professor William Hsiao of Harvard University (1994). He has taught at the University of Southern California (Assistant Professor, 1994-1999), North Carolina University (tenured professor, 2000-2006). In international academic activities, he served as chairman of 2004-2005 of “China Economic Association for the Study of American Economy” (www.ChinaCES.org), chairman of Asia Pacific Consortium of “Institute of International Medical Economics and Production Research” (www.ISPOR.org), and Associate editor of Value in Health, an international academic journal of the Society, editorial board member of International Applied Economics, and editor of the World Health, Nutrition, and Population Publishing editorial board. In domestic academic and policy advice, he currently serves as editor in charge of “China’s pharmaceutical economics”, member of the National Committee of Emergencies and Public Health Emergencies of the Ministry of Health, and invited editor of “China Health Economics”. His main research interests include health and economic growth, health care system reform, and cost-effectiveness analysis of pharmaceuticals. He has conducted a number of research projects on China’s medical system reform, health economy and population policy. He has worked with the Ministry of Health to conduct a systematic assessment of the “two rivers” pilots of China’s health insurance reform.